Data from: A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis

Gavin Giovannoni, Volker Knappertz, Joshua R. Steinerman, Aaron P. Tansy, Thomas Li, Stephen Krieger, Antonio Uccelli, Bernard M. J. Uitdehaag, Xavier Montalban, Hans-Peter Hartung, Maria Pia Sormani, Bruce A. C. Cree, Fred Lublin & Frederik Barkhof
Objective: To evaluate efficacy, safety, and tolerability of laquinimod in patients with primary progressive multiple sclerosis (PPMS). Methods: In the randomized, double-blind, placebo-controlled, phase 2 study ARPEGGIO (A Randomized Placebo-controlled trial Evaluating laquinimod in PPMS, Gauging Gradations In MRI and clinical Outcomes), eligible PPMS patients were randomized 1:1:1 to receive once-daily oral laquinimod 0.6 mg or 1.5 mg or matching placebo. Percentage brain volume change (PBVC; primary endpoint) from baseline to week 48 was assessed...
81 views reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
7 downloads reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?